Hologic Posts 6 Percent Increase in Q4 Revenues Driven Partly by Gen-Probe; Takes $1.11B Impairment Charge | GenomeWeb

NEW YORK (GenomeWeb News) — Hologic reported after the close of the market Monday a 6 percent increase in fiscal fourth quarter revenues, including a 14 percent spike in Diagnostics revenues driven primarily by the inclusion of a full quarter of Gen-Probe's sales.

For the three months ended Sept. 28, Hologic reported revenues of $622.1 million, up from $588.5 million in the same quarter last year, and falling short of the average Wall Street estimate of $624.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.